Temozolomide News and Research

RSS

Clinical trial tests effectiveness of chemotherapy after surgery for pancreatic neuroendocrine tumors

A new clinical trial is testing the effectiveness of chemotherapy treatment following surgery for a subset of pancreatic cancer patients.

19 May 2023

Novel immunotherapy appears to be safe, well tolerated by children with relapsed brain tumors

The first in-human-study of a new immunotherapy that blocks a natural enzyme tumors commandeer for their protection was well tolerated by children with relapsed brain tumors and enabled many to have unexpected months of a more normal life, researchers say.

25 Apr 2023

Study finds two substances capable of inhibiting proliferation of glioblastoma cells

Glioblastoma is a malignant tumor of the central nervous system (brain or spinal cord) and one of the deadliest types of cancer.

7 Mar 2023

Phase I clinical trial of PAC-1 in patients with end-stage cancers shows promising results

A phase I clinical trial of PAC-1, a drug that spurs programmed cell death in cancer cells, found only minor side effects in patients with end-stage cancers.

22 Dec 2022

Pt(IV)-conjugated drug-delivery system shows efficacy in glioblastoma therapy

A recent study demonstrated a novel method for delivering anti-cancer drugs, conjugated to modified cell-penetrating peptides across the blood-brain barrier, in mice to treat glioblastoma.

18 Nov 2022

Researchers take a cue from viruses to make glioblastoma more vulnerable to treatment

In the tough war against glioblastoma, scientists are taking a cue from viruses on how to make the aggressive cancer more vulnerable to treatment.

1 Nov 2022

The risk of adverse reactions when herbal medications are taken with cancer drugs

A new study discusses phytovigilance initiatives based on the real-world use of herbal drugs in cancer along with conventional chemotherapy.

24 Aug 2022

New glioma drug may represent a paradigm for designing therapeutics exploiting specific DNA repair

A new class of glioma drugs exploits tumors that lack the DNA repair enzyme MGMT; the drugs lead to the generation of cytotoxic DNA and selectively kill tumor cells without the risk of resistance, researchers report.

29 Jul 2022

Repurposing an antipsychotic drug to treat various types of cancer

To treat some of the psychosis issues associated with Parkinson's disease, physicians often prescribe pimavanserin, an antipsychotic drug that acts within the brain to prevent hallucinations and delusions.

28 Jul 2022

Researchers identify biomarkers that could be targets for novel drugs to treat glioblastoma

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Center, providing hope for a cancer that is highly lethal.

22 Jun 2022

Infiltrating gliomas are shaped by genetic evolution and microenvironment, finds study

Researchers have discovered that infiltrating gliomas, a common brain and spinal cord tumor, are shaped by their genetic evolution and microenvironment, a finding that could lead to more targeted treatments.

9 Jun 2022

Drug combination yields highest response and longest survival rates for patients with pancreatic NETs

Very few treatment options are available to patients with advanced pancreatic neuroendocrine tumors (NETs), but researchers at the Yale Cancer Center and Yale New Haven Health's Smilow Cancer Hospital found that patients treated with a combination of capecitabine and temozolomide had longer progression-free survival rates than those treated with temozolomide alone.

6 Jun 2022

Novel photonic technology could enable fluorescent sensors to track molecules deep inside the body

Fluorescent sensors, which can be used to label and image a wide variety of molecules, offer a unique glimpse inside living cells.

30 May 2022

Treatment with Tumor Treating Fields triggers downstream anti-tumor cell response, study finds

Novocure announced that a new study published in the Journal of Clinical Investigation (JCI) finds treatment with Tumor Treating Fields (TTFields) mediated cell disruption activates the immune system and triggers an anti-tumor cell response that may be effectively used together with existing immunotherapy approaches in the treatment of solid tumors, with limited systemic toxicity.

25 Feb 2022

Treatment with immune-boosting protein and radiation improves survival in mice with glioblastoma

Glioblastoma, an aggressive cancer in the brain or spinal cord, has proven stubbornly resistant to newer immunotherapies. And radiation and chemotherapy, the standard treatment for glioblastoma, result in fewer than 10% of patients surviving longer than five years after diagnosis.

19 Jan 2022

Folic acid-like drug reprograms DNA methylome of aggressive brain tumors

A folic acid-like drug, L-methylfolate, when administered alongside the standard therapy for patients with recurrent glioblastoma, changed aDNA process within their brain tumors, according to results from a phase 1 clinical trial.

5 Jan 2022

Scientists develop new approach to combat treatment-resistant melanoma

Researchers from the Centenary Institute have developed a new approach to fighting melanomas that fail to respond – or are resistant – to standard treatments. The deadliest form of skin cancer, melanoma is responsible for more than 1,700 deaths each year in Australia.

30 Oct 2021

Researchers develop new method to track the development of cancer cells

Changes in individual cancer cells over time may explain why brain tumours develop so differently, and why some cancer cells are resistant to certain treatments.

20 Sep 2021

Two studies on gastrointestinal stroma tumors describe advances that may lead to new treatments

Gastrointestinal stroma tumors (GIST) are cancers that start in specialized nerve cells found in the digestive system, from the esophagus and stomach to the intestines and rectum.

25 Aug 2021

KIYATEC’s test results accurately predict treatment response in recurrent high-grade glioma patients

KIYATEC, Inc. announced today the publication of new peer-reviewed data that establishes clinically meaningful prediction of patient-specific responses to standard of care therapy, prior to treatment, in newly diagnosed glioblastoma (GBM) and other high-grade glioma (HGG) patients.

18 Jun 2021